6 hours ago
2
Suriphon Singha/iStock via Getty Images
- Personalis (NASDAQ:PSNL) said it has expanded its partnership with Tempus AI (NASDAQ:TEM) to include colorectal cancer in their exclusive commercialization agreement.
- This collaboration will focus on launching the NeXT Personal test, which is designed to detect cancer recurrence in breast, lung, and
English (US) ·